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Abstract
One of the major causes of morbidity and mortality in man and economically important animals is bacterial infections of the
gastrointestinal (GI) tract. The emergence of difficult-to-treat infections, primarily caused by antibiotic resistant bacteria,
demands for alternatives to antibiotic therapy. Currently, one of the emerging therapeutic alternatives is the use of lytic
bacteriophages. In an effort to exploit the target specificity and therapeutic potential of bacteriophages, we examined the
utility of bacteriophage tailspike proteins (Tsps). Among the best-characterized Tsps is that from the Podoviridae P22
bacteriophage,whichrecognizesthe lipopolysaccharidesofSalmonellaentericaserovarTyphimurium.Inthisstudy,weutilized
a truncated, functionally equivalent version of the P22 tailspike protein, P22sTsp, as a prototype to demonstrate the
therapeutic potential of Tsps in the GI tract of chickens. Bacterial agglutination assays showed that P22sTsp was capable of
agglutinating S. Typhimurium at levels similar to antibodies and incubating the Tsp with chicken GI fluids showed no
proteolyticactivityagainst theTsp. Testing P22sTsp against the three major GI proteases showedthatP22sTsp was resistantto
trypsin and partially to chymotrypsin, but sensitive to pepsin. However, in formulated form for oral administration, P22sTsp
was resistant to all three proteases. When administered orally to chickens, P22sTsp significantly reduced Salmonella
colonization in the gut and its further penetration into internal organs. In in vitro assays, P22sTsp effectively retarded
Salmonella motility, a factor implicated in bacterial colonization and invasion, suggestingthatthe in vivo decolonization ability
of P22sTsp may, at least in part, be due to its ability to interfere with motility… Our findings show promise in terms of opening
novel Tsp-based oral therapeutic approaches against bacterial infections in production animals and potentially in humans.
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Introduction
Bacterial infections are one of the major causes of morbidity and
mortality in both man and economically important animals and
impose a huge economical burden in terms of health care cost, lost
manpower and contaminated food. Antibiotics are widely used
and in some places are the only treatments available. However,
due to the emergence of difficult-to-treat infections caused by
antibiotic resistant bacteria, there is an urgent need for
alternatives. Several other therapeutic approaches involving
passive and active immunization, toxin binding agents, lytic
bacteriophages, anti-bacterial peptides, phage lytic enzymes and
probiotics have been used but they are far from replacing the
antibiotic therapy approach [1–9].
Lytic bacteriophages are the natural enemy of their host
bacteria and, as such, provide a natural solution for the therapy of
bacterial infections. Bacteriophages are also host specific, self-
replicating, self limiting and virtually non-toxic. These character-
istics have made lytic bacteriophages attractive therapeutic agents
to combat bacterial infections. Despite their widely known
therapeutic potential, bacteriophages have still not filled the gap
of desperately needed alternatives to current antibacterial agents.
Antibacterial activities of bacteriophages have been tested in
several animal studies but led to, often, mixed outcomes [10–15].
Bacteriophage therapy is associated with drawbacks such as the
possibility of showing reduced efficacy under anaerobic conditions
in the gut due to bacterial regrowth [16], the emergence of phage-
resistant bacteria and the risk of horizontal gene transfer of
virulence traits to the bacteria potentially rendering the target
organism even more pathogenic [17–19].
To exploit the target specificity and therapeutic potential of
bacteriophages without being held back by some of the drawbacks
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13904associated with using whole phages, we chose to investigate the
utility of bacteriophage tailspike proteins (Tsps). Tsps are
components of the tail apparatus of many bacteriophages, and
mediate the specific recognition of its bacterial host by binding to
surface structures such as polysaccharides [20–27]. Additionally,
many Tsps have endoglycosidase activity, hydrolyzing their
polysaccharide receptors. Tsps identified to date are homotrimers
consisting of an N-terminal capsid-binding domain, a central
domain that binds/hydrolyzes the O-antigen region of bacterial
surface lipopolysaccharides and a C-terminal region crucial for
trimerization. A hallmark of Tsps is their high stability. Tsps, as
well as their N-terminal truncated versions, are protease resistance,
have excellent thermostability, show resistance to dissociation in
high concentrations of urea and SDS, and reversibly unfold in
concentrated chemical denaturants [23,25,26–29]. One well
studied Tsp is that of bacteriophage P22 which is a 215-kDa
trimeric protein specifically recognizing several pathogenic
Salmonella spp. including S. enterica serovar Typhimurium [30–
33]. The shortened version of P22 phage Tsp (P22sTsp) lacking
the N-terminal capsid-binding domain exhibits the same native
structure, oligosaccharide binding and endorhamnosidase activity
as the full-length Tsp [28,29,33]. Similar to the full-length Tsp, the
shortened P22 Tsp exhibits impressive solubility and stability
properties: it is SDS- and trypsin-resistant as well as thermostable
at temperatures beyond 80uC [28,29,34,35].
Here, we tested the idea of using bacteriophage Tsps as an
alternative to the whole phage approach for oral therapy of
bacterial gut infections. The general stability of Tsps and their
resistance to proteases makes Tsps - as well as their shortened
derivatives - ideal proteins for oral therapeutics as they can better
resist the acid-induced denaturation and digestion by proteases in
the gastrointestinal (GI) tract. In this study we show that the
Salmonella-specific P22sTsp is effective in reducing Salmonella
colonization in the gut of chickens and the penetration into
internal organs. Our findings show promise in terms of opening
novel oral Tsp-based therapeutic approaches against bacterial
infections in both man and production animals that provide many
advantages over the use of intact bacteriophages including reduced
ability of the pathogen to develop resistance and release of harmful
bacterial cell components during lysis.
Results
P22sTsp agglutinates Salmonella cells similar to
antibodies
The ability of P22sTsp to agglutinate Salmonella cells was
assessed in cell micro-agglutination assays. Because P22sTsp is
multimeric, it is expected to cross-link and agglutinate the bacterial
cells. In micro-agglutination assays, bacteria that are not
agglutinated settle to the center of the well forming a dot and
those that are agglutinated form a sheet across the well [36]
(Figure 1). Micro-agglutination was performed by incubating a
constant number of bacterial cells with two-fold dilutions of
P22sTsp.
The agglutination ability of P22sTsp was assessed at 4uC and
42uC. At 4uC, the minimum concentration of P22sTsp resulting in
detectable cell agglutination (minimum agglutination concentra-
tion) was 149 ng/ml (Figure 1). P22sTsp showed slightly better
agglutination than the Se155-4 antibody [37], which is specific to
the O-antigen of Salmonella enterica serovar Typhimurium (mini-
mum agglutination concentration =320 ng/ml). The agglutina-
tion was specific since P22sTsp did not agglutinate the control
organism, Staphylococcus aureus (Figure 1). No agglutination was
observed at 42uC (physiological body temperature in chickens)
under the examined assay conditions. This can be attributed to the
endorhamnosidase activity of P22sTsp interfering with its binding
to Salmonella and subsequent agglutination, an activity which is
presumably suppressed at 4uC. Consistent with this view, a
P22sTsp mutant (D392N; [33]) with wild-type binding affinity and
defective endorhamnosidase activity agglutinates Salmonella at
42uC (unpublished results).
P22sTsp is significantly resistant to GI proteases
In the present study, P22sTsp was fed to chickens in order to
assess its ability to reduce Salmonella colonization in the gut. The
decolonizing efficacy of P22sTsp would depend on its degree of
resistance to GI proteases, particularly to trypsin, chymotrypsin
and pepsin, the major GI proteases. We, thus, performed a series
of GI protease digestion experiments to obtain the resistance
profile of P22sTsp. In the first set of experiments, susceptibility of
P22sTsp to proteases present in chicken GI fluids was tested.
P22sTsp was shown to be completely resistant to GI fluid proteases
even after 2 h of incubation at 37uC, whereas a control antibody
protein was completely digested (Figure 2A). Also, the antibody
control was not digested when incubated with heat-inactivated GI
fluid for 2 h at 37uC, demonstrating that the banding pattern was
due to proteases in the GI fluids (data not shown). The P22sTsp
was also shown to be completely resistant to trypsin (Figure 2B),
but somewhat sensitive to chymotrypsin (Figure 2C) and
completely sensitive to pepsin digestion (data not shown).
However, when 10% bovine serum albumin (BSA) was included
in the digestion reactions, chymotrypsin and pepsin did not digest
P22sTsp anymore, demonstrating the protective role of BSA
against these proteases (Figure 2D). Thus, to diminish the possible
adverse effects of variable GI proteases in vivo, the following
formulation was chosen for the animal studies: P22sTsp suspended
in PBS (pH 7) containing 10% BSA.
P22sTsp reduces Salmonella colonization in the gut and
bacterial penetration into internal organs
Next, we set out to investigate, in a series of animal studies, the
effect of oral administration of P22sTsp in reducing Salmonella
colonization in chicks. Subsequent to Salmonella colonization of the
GI tract, the organism has been shown to translocate through the
gut into the bloodstream, leading to substantial infection of the
liver and spleen [38–41]. Thus, the effect of treatment was assessed
by counting the number of viable Salmonella not only in the gut
(cecum) but also in the liver and spleen.
For the animal studies, two-day-old chicks were orally infected
with Salmonella (10
4 to 10
7 colony-forming units (CFU), depending
on the experiment) and were subsequently fed with 3 doses of
P22sTsp (in PBS/10% BSA). In preliminary experiments two
different treatment protocols were tested (Protocol 1 and Protocol
2, Figure 3). The first dose of Tsp in Protocol 1 was given one hour
after infection of chicks with Salmonella (10
7 CFU) and in Protocol
2, the dose was delayed and given at time 18 h post infection.
Following the first dose, the second and third doses were given in
24-hour time intervals in both protocols. Chicks were then
sacrificed 5 h after receiving the third dose and their Salmonella
contents were enumerated in the cecum, liver and spleen.
P22sTsp treatment of infected animals led to a significant
reduction of Salmonella in the cecum, liver and spleen in Protocol 1
(P,0.05) but not in Protocol 2 (Figures 4A and 4B). Infected
animals receiving Tsp treatments under Protocol 1 (S.typh.+Tsp/
BSA (P1)) and Protocol 2 (S.typh.+Tsp/BSA (P2)) showed at least
100- and 10-fold reduction of bacterial titre in their ceca,
respectively (P1 median=3.3610
4 CFU/ml; P2 median=
7.8610
5 CFU/ml), compared to control groups which were
Tailspike Protein Therapeutics
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(S.typh.+BSA) or not treated (S.typh.) (medians: 5.9610
6 CFU/
ml and 3.2610
6 CFU/ml, respectively, Figure 4A).
Examination of bacterial infection in the liver and spleen
showed the same overall pattern as those for the cecum (Figures 4A
and 4B). Salmonella was detected in the livers and spleens of 65–
73% of the control group that was treated with BSA alone
(S.typh.+BSA) and 60% of the non-treated control group (S.typh.).
Percentages of livers infected were significantly lower for animals
that were treated according to Protocol 1 (P,0.0001) but not
Protocol 2 compared to the BSA-treated groups (Table 1).
However, both protocols were effective in reducing the infection
in the spleens of Tsp-treated animals compared to the BSA-treated
controls (P,0.0001), with Protocol 1 being more effective than
Protocol 2 (P,0.0001; Table 1).
Protocol 1 was then used in all subsequent trials. Two-day-old
chicks were divided into two groups, each consisting of 3 cages
with 8 chicks (total of 24 per group, Figure 5). Following
inoculation with either 10
4 bacteria (Group 1) or 10
5 bacteria
(Group 2), one cage in each group received BSA (S.typh.+BSA)
while the other two received P22sTsp (S.typh.+Tsp/BSA). Ceca of
Tsp-treated chicks (S.typh.+Tsp/BSA), from groups 1 and 2,
Figure 1. P22sTsp micro-agglutination assay at 4uC. P22sTsp agglutinates Salmonella effectively as shown by the diffused cell patterns (wells
on the left side of the arrow). No agglutination was observed with Staphylococcus aureus (lower panel) at the highest concentration used (cell
sediments appear as round dots). MAC: minimum agglutination concentration.
doi:10.1371/journal.pone.0013904.g001
Figure 2. Protease resistance profile of P22sTsp. SDS-PAGE analysis of P22sTsp following treatment with A, chicken GI fluid proteases, B,
trypsin, C, chymotrypsin and D, pepsin and chymotrypsin in the presence or absence of 10% BSA. A, Lane 1, molecular weight markers; lane 2,
untreated P22sTsp; lanes 3–5, P22sTsp incubated with protease solutions at 37uC for 5 min, 20 min and 2 h, respectively. B, C, Lane 1, molecular
weight marker; lane 2, untreated P22sTsp; lane 3, trypsin-treated (B) or chymotrypsin-treated (C) P22sTsp (1 h at 37uC). A control protein (single-
domain antibody) incubated with the GI fluid (37uC, 2 h), trypsin or chymotrypsin (37uC, 1 h) showed complete digestion (data not shown). D, All
reaction samples, including controls (no proteases) were subjected to a purification step with PureProteome
TM Nickel Magnetic Beads prior to their
analysis by SDS-PAGE (see Materials and Methods). Digestion reactions were carried out for 0 and 60 min. The positions of the molecular weight
markers are indicated on the left of the panel D figures.
doi:10.1371/journal.pone.0013904.g002
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the BSA-treated cohort (Group 1, p=0.0007; Group 2, p=0.003,
Figure 5, Table 2). The reduction was 13- and 15-fold for group 1
(medians: 1.5610
7 CFU/ml and 1.2610
7 CFU/ml, cage 1 and
cage 2, respectively) and 13- and 70-fold for group 2 (medians:
6.6610
7 CFU/ml and 1.3610
7 CFU/ml, cage 1 and cage 2,
respectively) when compared to the BSA-treated animals (medi-
ans: 2.0610
8 CFU/ml and 9.1610
8 CFU/ml; group 1 and group
2, respectively). Pooled data from group 1 and group 2 of Tsp-
treated animals were compared to pooled data from BSA-treated
animals and showed a significant reduction in Salmonella counts in
the cecum, liver and spleen (Figure 5, Table 2).
P22sTsp retards the motility of Salmonella
Bacterial motility is implicated in colonization and invasion of
host cells by bacteria [42,43]. To verify if Tsp treatment of
Salmonella would affect bacterial motility, hence its virulence [44],
we performed bacterial motility assays. Salmonella cells were
applied at the centre of the motility plates with or without
P22sTsp throughout the plates and allowed to grow (circles). The
diameter of growth was calculated at different time points and
used as a measure of motility. The results clearly show that the
motility of Salmonella is significantly retarded in the presence of
P22sTsp (Figure 6).
Discussion
In this study we showed that oral administration of Salmonella-
specific shortened tailspike protein (P22sTsp) significantly reduced
Salmonella infection in chicks. Detailed studies are still required to
delineate the mode of action of P22sTsp in reducing Salmonella
colonization. However, one mechanism could be through the
ability of P22sTsp to retard the motility of Salmonella in vivo, a
possibility supported by our in vitro experimental results. This
motility-retarding ability of P22sTsps can be attributed to
their endorhamnosidase and/or binding activity capable of
‘‘modifying’’ O-antigen, hence, compromising the structure of
lipopolysaccharide. This is in line with previous studies showing
that (i) motility is a colonization factor for Salmonella which can be
retarded by altering the structural integrity of lipopolysaccharides,
(ii) the lipopolysaccharide O-antigen of a Salmonella is a significant
factor in gastrointestinal colonization of chicks, and (iii) a Salmonella
O-antigen-specific antibody inhibited Salmonella enterica serovar
Typhimurium motility and entry into epithelial cells [42–48]. Tsp-
mediated bacterial agglutination may also have a role in in vivo
decolonization, although P22sTsp did not agglutinate Salmonella in
vitro at physiological temperature under the conditions we tested
[49–51]. Given that bacterial motility and/or cell surface proteins
are often required for infection or retention of bacteria, blocking
these cell surface binding sites and/or reducing motility of the
bacteria will reduce the infectivity of the organism. It is unlikely
that the observed therapeutic effect of Tsp is related to a
generalized stimulation of the immune system due to endotoxin
contamination of Tsp preparations since phage crude lysates were
shown not to be toxic in 7-week old chickens [52] and the 2-day
old chicks used in the current study would have immature immune
systems [53].
If used in oral therapy, an effective decolonizing agent must be
somewhat resistant to proteolysis by GI proteases (pepsin, trypsin,
chymotrypsin) and able to withstand the low pH of the gastric
juice. In vitro digestion studies showed that P22sTsp was sensitive to
pepsin and somewhat sensitive to chymotrypsin. To diminish the
adverse effect of these enzymes in vivo, the administered P22sTsp
was formulated in 10% BSA and PBS (a physiological pH buffer),
since our in vitro digestion experiments indicated that 10% BSA
protected P22sTsp from digestion by pepsin and chymotrypsin.
With that high of a concentration, BSA presents 1000-fold more
potential chymotrypsin and pepsin cleavage sites than P22sTsp
(Table S1), and thus becomes the target for chymotrypsin and
pepsin digestion. These findings are in agreement with previous
ones which showed the co-presence of high concentrations of a
protein additive (10% BSA in the present case) protects the
therapeutic protein from proteolysis [54–57]. Furthermore, the
buffering capacity of the formulation (PBS) is also protective as it
Figure 3. Schematic overview of the two protocols used for animal studies. At time point zero, chicks were inoculated with 10
7 Salmonella.
In Protocol 1, chicks were gavaged after inoculation (1 h) with P22sTsp in 10% BSA or with 10% BSA alone. The next two gavages were given at 18 h
and 42 h. Chicks were sacrificed at 47 h. In Protocol 2, the first gavage was delayed by 17 h and given at 18 h. The next two gavages were given at
42 h and 66 h. The chicks were subsequently sacrificed at 47 h (Protocol 1) or 71 h (Protocol 2).
doi:10.1371/journal.pone.0013904.g003
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denaturing capability of acidic gastric juice [54,55,58,59]. This
may explain why P22sTsp was not digested with the GI fluid
which presumably contains pepsin. Formulation of P22sTsp in a
higher pH buffer than PBS, e.g., carbonate buffer, or using
encapsulation formats should provide P22sTsp with even better
protection against the acid-denaturing and peptic environment of
the stomach and lead to a more effective therapeutic effect in vivo
[55,59,60].
From the therapeutic point of view in the context of the GI tract
and mucosal surfaces in general, Tsps offer several advantages.
Tsps (i) can be expressed in E. coli in high amounts leading to
reduced production costs, (ii) maintain their clonal originality
during production, as opposed to intact phages which are prone to
frequent mutations, (iii) are stable molecules with significant
resistance against GI tract major proteases, (iv) reduce pathogen
load without lysing bacteria, hence no harmful bacterial products
are released, (v) are target specific and should not disturb the gut’s
normal microflora, (vi) should show reduced emergence of
resistance since Tsps do not threaten bacterial viability, (vii) are
expected to be nontoxic, as they are regularly consumed in foods
as part of phage (usually more than 10
8 phages per gram of meat)
and (viii) are amenable to protein engineering for improved
function. For example, Tsps can be engineered to have improved
stability, binding and avidity with novel, narrow or broad
specificities. They can also be modified to have additional effector
functions by means of fusion to toxins. Other novel functions such
as agglutination capabilities at physiological temperatures can be
imparted on Tsps through mutations that eliminate the enzymatic
activity, but retain the binding activity [25,33].
While the immediate therapeutic inference of the present
findings concerns the treatment of chickens for a more economic
production of meat [61–64], it has far-reaching implications. One
source of human infection with Salmonella is through contaminated
meat and therefore Tsp treatment of chickens constitutes a
prevention-at-source strategy. The concept of the prevention-at-
source strategy is also an attractive one in the case of infections
caused by human pathogens such as E. coli O157:H7, a bacterium
which is a commensal in cattle and infects humans through
contaminated food and water. This prophylactic treatment is more
effective and less costly than the downstream treatment of infected
individuals. In this regard, incorporation of Tsps into feed and/or
water for animals may prove to be a very practical and cost
effective preventative measure for both animals and humans. The
Tsp therapy approach can be extended to bacterial infections in
humans and ‘‘production animals’’ such as cows, pigs, fish and
other livestock in general. In humans, in particular, oral therapy
with Tsps, may be useful in combating pathogens such as
Clostridium difficile or E. coli O157:H7 [65].
Materials and Methods
Cells, phage and P22sTsp
S. enterica serovar Typhimurium (ATCC19585), S. aureus
(ATCC12598) and P22 phage (ATCC19585-B1) were purchased
from the American Type Culture Collection (Manassas, VA).
P22sTsp cloning, expression and preliminary characterization is
described in a separate publication. Briefly, the truncated form of
the P22 tailspike protein (P22sTsp) [29] spanning amino acid
residues 109-666 was cloned and expressed in E. coli. P22sTsp
Figure 4. Effect of orally administered P22sTsp on Salmonella
colonization of chick cecum. Effect of orally administered P22sTsp
on Salmonella colonization of chick cecum (A) or liver and spleen (B).
Medians are shown as horizontal bars on graph A. The two protocols
were compared and for subsequent studies Protocol 1 was used. Chicks
not infected with Salmonella Typhimurium (No S.typh.); chicks infected
with S. Typhimurium but did not receive any treatment (S.typh.);
infected chicks treated with 10% BSA (S.typh.+BSA); infected chicks
treated with P22sTsp in 10% BSA according to Protocol 1 (S.typh.+Tsp/
BSA (P1)); infected chicks treated with P22sTsp in 10% BSA according to
Protocol 2 (S.typh.+T s p / B S A( P 2 ) ) .F o rc e c a lr e s u l t s ,t h eo v e r a l l
treatment effect was assessed using the Kruskal-Wallis test with
Dunnett’s post test to correct for the number of comparisons and
was significant (P,0.05). For liver and spleen results, all pairs were
compared to each other using the chi square test. Not significant (ns).
doi:10.1371/journal.pone.0013904.g004
Table 1. Comparative study of two different treatment
protocols.
Infected/not infected P values (chi square)
Cont.
(+/2)
P1
(+/2)
P2
(+/2)
Cont. vs P1Cont. vs P2P1 vs P2
Liver 64/36 22/78 56/44 P,0.0001 ns P,0.0001
Spleen 73/27 11/89 33/67 P,0.0001 P,0.0001 P,0.0001
Protocol 1 (P1); Protocol 2 (P2); Control (Cont.); Not significant (ns); Percentage
infected with Salmonella versus not infected (+/2). The Chi square test was
used to compare pairs. P values less than 0.05 were considered significant.
doi:10.1371/journal.pone.0013904.t001
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immobilized metal affinity chromatography. P22sTsp expression
yielded 25–50 mg of purified soluble protein per litre of bacterial
culture.
Growth of bacteria
To prepare cells for micro-agglutination assays, a single S.
Typhimurium colony from a nutrient agar plate was used to
inoculate 15 ml of nutrient broth (NB) and was grown overnight at
37uC with shaking at 250 rpm. The culture was centrifuged,
washed with PBS buffer, re-centrifuged and subsequently re-
suspended in cold PBS. The cell density was adjusted to an OD600
of 1 (1 OD600 =1 610
8 cells/ml) with PBS. S. aureus was grown as
described for S. Typhimurium, but in brain heart infusion media.
To prepare cells for in vivo experiments, a frozen stock of S.
Typhimurium was streaked onto a xylose lysine deoxycholate
(XLD) plate (Oxoid Company, Nepean, ON, Canada) followed by
incubation at 37uC for 18–24 h. Three millilitres of overnight
culture (in NB) was started from a single colony of S.
Typhimurium on an XLD plate, and grown at 37uC. This culture
would typically have an OD600 of approximately 1.4–1.6. A 1:100
dilution of bacterial cells in 2610 ml NB was made and the cells
were grown at 37uC until they reached an OD600 of 0.3–0.5 (,2–
3 h). Cells were centrifuged at 12,000 g and re-suspended in PBS
to a final OD600 of 1.0. Serial dilutions of the cell culture, on XLD
plates, were also performed to confirm the cell density. Cells were
immediately used to orally inoculate chicks.
Micro-agglutination assay
S. Typhimurium micro-agglutination assays were performed
with P22sTsp or the Se155 IgG control in microtitre plates at 4uC
or 42uC [36]. Fifty microlitres of S. Typhimurium or control
Figure 5. Effect of orally administered P22sTsp on Salmonella colonization of chick cecum, liver and spleen at an inoculation level of
10
4 (Group 1) and 10
5 (Group 2) bacteria. Medians are shown as horizontal bars on the graphs. Protocol 1 was followed. The P22sTsp treatment
in each group was done in duplicate (cage 1 and cage 2). Non-inoculated chicks remained pathogen free (n=9) and are not included in the graph.
Infected chicks treated with 10% BSA (S.typh.+BSA); infected chicks treated with P22sTsp in 10% BSA (S.typh.+Tsp/BSA). The data from S.typh.+BSA
cohorts of group 1 and group 2 were pooled, since there was no significant difference between the two groups (Mann Whitney two-tailed t-test,
cecum: P=0.32; liver: P=0.23; spleen: P=0.5). Pooled data for Tsp-treated animals includes 4 cohorts (2 cages, two groups). For comparison within
the groups see Table 2.
doi:10.1371/journal.pone.0013904.g005
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Subsequently, two-fold serial dilutions of P22sTsp or Se155 IgG in
PBS (50 ml) were added to wells. Plates were incubated overnight
at 4uCo r4 2 uC. In a micro-agglutination assay, agglutinated cells
appear diffused whereas the non-agglutinated ones appear as
round dots at the bottom of the wells. The minimum
concentration of P22sTsp which resulted in detectable cell
agglutination (minimum agglutination concentration) was deter-
mined and used as a measure of agglutination potency of P22sTsp.
Preparation of GI fluid protease solution
To prepare the GI fluid protease solution, four chicks were
sacrificed and the GI contents were squeezed out of the GI tract
and weighed. The appropriate amount of sterile PBS was added to
make a 10-fold dilution. The sample was centrifuged at 1000 g for
15 min at 4uC and 1-ml aliquots of the supernatant was
transferred to microfuge tubes and spun at maximum speed to
pellet down any remaining debris. The supernatants were frozen
at 220uC and stored in small aliquots for future digestion
experiments.
Protease digestion experiments
Freshly-prepared sequencing grade trypsin or chymotrypsin
(Hoffmann-La Roche Ltd., Mississauga, ON, Canada) in 1 mM
HCl were used for digestion experiments. One microlitre of
0.012 mg/ml trypsin or chymotrypsin was mixed with 8 mlo f
0.3 mg/ml P22sTsp in 100 mM Tris-HCl buffer pH 7.8 (trypsin) or
in 50 mM Tris-HCl buffer pH 7.8 plus 20 mM CaCl2 (chymo-
trypsin). Reactions were carried out in a total volume of 10 ml for
up to 1 h at 37uC and stopped by adding 1 ml of 0.1 mg/ml
trypsin/chymotrypsin inhibitor (Sigma-Aldrich Canada Ltd.).
Following completion of digestion, samples were mixed with
SDS-PAGE loading buffer, incubated for 5 min at 95uC and
analyzed by PhastSystem SDS-PAGE according to the manufac-
turer’s instructions (GE Healthcare). Pepsin digestion mixtures
contained 8 ml of 0.3 mg/ml P22sTsp, 1 ml of 100 mM HCl and
1 ml of 0.012 mg/ml pepsin (Sigma-Aldrich Canada Ltd.). Reac-
tions were carried out at 37uC for up to 1 h and were subsequently
analyzed by SDS-PAGE as described above.
To carry out digestion experiments with the GI fluid protease
solution, frozen stocks (see above) were thawed, diluted 10-fold,
and 30 ml of the diluted samples was mixed with 50 mg of P22sTsp.
Reactions were carried out in PBS buffer in a total volume of 80 ml
at 37uC for up to 2 h. The reactions were stopped by immediately
boiling the samples for 5 min. In protease-negative experiments,
30 ml of inactivated GI fluid was used (inactivated samples were
prepared by heating chick intestinal tract fluid at 95uC for 15 min
followed by cooling down on ice). In P22sTsp-negative control
experiments, P22sTsp was replaced with a control protein.
Following completion of the digestions, aliquots were removed
and analyzed by SDS-PAGE.
The sensitivity of P22sTsp to chymotrypsin and pepsin in the
presence and absence of 10% (w/v) BSA (Fraction V, Minimum
98%, Sigma) was compared. One microlitre of 0.1 mg/ml
chymotrypsin, 40 ml of 0.5 mg/ml P22sTsp and 360 mlo f
100 mM Tris-HCl buffer pH 7.8 plus 20 mM CaCl2 were
combined. For the pepsin digestion experiment, 40 ml of 0.5 mg/
ml P22sTsp and 340 ml of PBS were combined. The pH of the
reaction mixture was adjusted to 2.0 by adding 20 ml of 1 M HCl
followed by the addition of 1 ml of 0.1 mg/ml pepsin. Reactions
were carried out in a total volume of 400 ml with or without 10%
BSA at 37uC for 1 h and stopped by adding 16 ml of 25x protease
inhibitor cocktail (Hoffmann-La Roche Ltd.) to the chymotrypsin
digestion or by raising the pH of the reaction mixture to 7–8 with
1 M NaOH for the pepsin digestion. Subsequently, PureProteo-
me
TM Nickel Magnetic Beads (Millipore, Billerica, MA) were used
to purify His-tagged P22sTsp away from the bulk BSA in the
reaction mixtures. The optimal pH for the binding of the nickel
beads to the His tag, according to the manufacturer, is 7.5–8.0.
After adding 400 ml of the binding buffer (50 mM Tris-HCl/
500 mM NaCl/20 mM imidazole pH 7.5) to the 400 ml termi-
nated digestion reactions, including those without 10% BSA, the
pH of the reaction mixtures was determined and adjusted to 7.5 to
8.0, if necessary. Fifty microlitres of magnetic beads, equilibrated
with the binding buffer, was added to the 800 ml mixture and was
incubated for 30 min at 37uC on a desktop rotor. Three
consecutive washes were performed with the binding buffer to
remove the BSA followed by the elution of nickel-bound P22sTsp
with 100 ml of 50 mM Tris-HCl/500 mM NaCl/500 mM
imidazole, pH 7.5. Eluted P22sTsp was mixed with SDS-PAGE
loading buffer, incubated for 5 min at 95uC and analyzed by SDS-
PAGE.
Table 2. Effect of P22sTsp on reducing Salmonella
colonization in the cecum, liver and spleen of two-day-old
chicks.
Group 1
All
cohorts
1
Cage 1 vs
Cont.
Cage 2 vs
Cont.
Cage 1 vs
Cage 2
Cecum P,0.001 P,0.01 P,0.01 ns
Liver ns ns ns ns
Spleen ns ns ns ns
Group 2
Cecum P,0.01 ns P,0.01 ns
Liver P,0.05 P,0.05 P,0.05 ns
Spleen P,0.05 P,0.05 ns ns
Control (Cont.); not significant (ns). Group 1 was treated with 10
4 bacteria and
group 2 with 10
5 bacteria. Each group consisted of 3 cohorts: Control (Cont)
and duplicate treatment cohorts, Cage 1 and Cage 2.
1Three unpaired cohorts in each group were compared using the Kruskal-Wallis
test with Dunnett’s post test to correct for the number of comparisons.
P values less than 0.05 were considered significant.
doi:10.1371/journal.pone.0013904.t002
Figure 6. P22sTsp reduces Salmonella motility. The spread of
Salmonella representative of its motility on soft agar plates was
measured at different time points and used to plot a graph of motility
diameter versus incubation time.
doi:10.1371/journal.pone.0013904.g006
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Motility plates (NB plates/0.4% agar with or without 25 mg/ml
filter-sterilized P22sTsp) were made the day before their use and
left at room temperature. Purified P22sTsp was buffer-exchanged
by size exclusion chromatography (Superdex
TM 200 column, GE
Healthcare) using PBS as the equilibration buffer and then added
to the molten motility media just before pouring them into plates
(50uC). To perform motility assays, Salmonella cells were grown on
NB plates overnight at 37uC (16–18 h). Cells were subsequently
suspended in sterile PBS at a cell density of 1 OD600. Employing a
10-ml pipettor, 5 ml of the cell suspension was used to inoculate the
centre of the motility plates, lightly piercing the surface of the agar
plate with the pipettor tip; the plates were left unmoved until the
inoculation spots became dry. The plates were then incubated at
37uC. At different time points, the dimensions of the Salmonella
zones of motility were measured. In control experiments, an equal
volume of PBS replaced P22sTsp.
Animal studies
Leghorn chicks were obtained from the Canadian Food
Inspection Agency one day after hatch. The animals were
maintained and used in accordance with the recommendations
of the Canadian Council on Animal Care Guide to the Care and
Use of Experimental Animals. The experimental procedures were
approved by the institutional animal care committee (Protocol
Number 2004-20). One-day-old chicks were provided with feed
and water ad libitum and cared for in accordance to the approved
guidelines of the Canadian Council for Animal Care. For
determining the presence of endogenous Salmonella, cloacal swabs
were taken from 10% of the chicks, selected at random, with
calcium alginate swabs (Fisher Scientific, Ottawa, ON, Canada).
XLD plates were streaked with the swabs and incubated at 37uC
overnight. The presence of Salmonella was identified as black
colonies on the red/pink XLD plate.
Infection of 2-day-old chicks was done by oral gavaging the
animals with 10
4–10
7 Salmonella/300 ml PBS. Subsequently,
chicks were gavaged a total of 3 doses of P22sTsp (30 mg/
300 ml) in 10% BSA or with 10% BSA alone. The 3 oral doses
were given at 1 h, 18 h and 42 h (Protocol 1) or at 18 h, 42 h and
66 h (Protocol 2) post-infection and the chicks were subsequently
sacrificed at 47 h (Protocol 1) or 71 h (Protocol 2). Following
sacrifice, the cecal materials, livers and spleens were collected
and processed for determination of Salmonella titre as described
below.
Cecal material. The cecal samples were weighed (#0.2 g),
diluted in PBS (10
21 dilution) and vortexed. Further serial
dilutions up to 10
26 were performed in 200 ml of PBS in 96-well
microtitre plates using a multi-channel pipettor. Starting from the
highest dilution, 50 ml was plated on XLD plates. The plates were
allowed to dry and subsequently incubated at 37uC overnight. The
bacterial counts from the serial dilutions were determined the next
day.
Liver and spleen. To homogenize samples, two Bio 101 J’’
ceramic beads (Qbiogene, Carlsbad, CA) were placed in 2-ml
screw cap tubes (Diamed, Mississauga, ON, Canada). Sterile PBS
was added to spleen samples (600 ml) or liver samples (800 ml,
which were cut from the right front lobe of liver) and kept on ice
prior to placing them in the Fastprep Instrument (Qbiogene). Fifty
microlitres of the homogenized samples, which resulted in
countable colonies, were plated on XLD plates. Plates were
incubated overnight at 37uC and the bacterial counts were
determined in the morning. Any infected liver with lower than 24
bacteria (2 times the 1/12 dilution factor) or infected spleen with a
bacterial count lower than 32 (2 times the 1/16 dilution factor) was
below the detection limit of this method.
Statistics
We assumed a non-Gaussian distribution of the data and
therefore used non-parametric tests. To compare 3 or more
unpaired groups, the Kruskal-Wallis test with Dunnett’s post test
was performed to correct for the number of comparisons. Medians
of two unpaired groups were compared using the two-tailed non-
parametric t-test (Mann-Whitney test). The chi square test was
used to compare the pairs. P values less than 0.05 were considered
significant. All analyses were performed using GraphPad Prism
version 4.02 for Windows (GraphPad Software, San Diego, CA;
‘‘www.graphpad.com’’).
Supporting Information
Table S1 Theoretical number of cleavage sites for P22sTsp and
BSA.
Found at: doi:10.1371/journal.pone.0013904.s001 (0.03 MB
DOC)
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